Gyre Therapeutics, Inc.GYRENASDAQ
Loading
GYRE Revenue Growth (YoY Quarterly)•+33.45%
Stock Alarm Pro
Growth Metrics
Latest: Q4 2025vs Q3 2025
Revenue GrowthGross Profit GrowthEBITDA GrowthOperating Income GrowthNet Income GrowthEPS GrowthEPS Diluted GrowthWeighted Average Shares GrowthWeighted Average Shares Diluted GrowthDividends per Share Growth
+33.45%
+13.5pp
+32.80%
+14.8pp
-90.12%
-166.0pp
-80.23%
-143.8pp
+0.00%
-221.2pp
+0.00%
+31.5pp
+0.00%
+28.5pp
+7.12%
+3.1pp
+791.12%
+791.1pp
+0.00%
+0.0pp
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +2.67% | -18.82% | +6.13% | +19.92% | +33.45% |
| Gross Profit Growth | +3.08% | -19.20% | +4.76% | +17.96% | +32.80% |
| EBITDA Growth | +0.00% | -66.91% | -19.63% | +75.87% | -90.12% |
| Operating Income Growth | +0.00% | -71.84% | -33.45% | +63.60% | -80.23% |
| Net Income Growth | +0.00% | -64.18% | -87.47% | +221.17% | +0.00% |
| EPS Growth | +0.00% | -66.85% | -87.89% | -31.51% | +0.00% |
| EPS Diluted Growth | +0.00% | -94.14% | -93.49% | -28.48% | +0.00% |
| Weighted Average Shares Growth | +11.10% | +3.79% | +4.23% | +4.06% | +7.12% |
| Weighted Average Shares Diluted Growth | +33.55% | -0.61% | -1.56% | +0.06% | +791.12% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -182.08% | -104.47% | +0.00% | +179.00% | +0.00% |
| Free Cash Flow Growth | -438.45% | -135.81% | +0.00% | +306.21% | +0.00% |
| Receivables Growth | +73.13% | +34.48% | +27.37% | +24.56% | +26.73% |
| Inventory Growth | +48.03% | +59.51% | +57.25% | +38.80% | +60.50% |
| Asset Growth | +7.61% | +6.38% | +26.23% | +27.26% | +32.48% |
| Book Value per Share Growth | +0.00% | +15.88% | +46.30% | +55.03% | +56.32% |
| Debt Growth | +290.71% | +476.36% | -28.78% | -35.10% | -41.24% |
| R&D Expense Growth | -18.74% | +41.84% | +2.09% | -14.85% | +29.71% |
| SG&A Expenses Growth | -15.83% | -0.90% | +12.25% | +12.13% | +36.72% |
1 / 4